Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Kimco Realty Corporation (HC) Common Stock (KIM) vs Moderna, Inc. (MRNA) Price & Performance

Kimco Realty Corporation (HC) Common StockTrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

Kimco Realty Corporation (HC) Common Stock vs Moderna, Inc. — how do they compare? Kimco Realty Corporation (HC) Common Stock trades at $22.16 (market cap $14.82B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 5.3× Kimco Realty Corporation (HC) Common Stock's market cap, and Kimco Realty Corporation (HC) Common Stock pays a 5.07% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kimco Realty Corporation (HC) Common Stock for 1 Days and Moderna, Inc. for 59 Days on average.

KIMMRNA
Market Cap
$14.82B$78.65B
Volume
5,158,46237,373,437
Sector
Real EstateHealth
52-Week High
$26.38$203.46
52-Week Low
$19.78$22.36
Typical Hold Time
1 Days59 Days
Enterprise Value
$22.98B$74.80B
Dividend Yield
5.07%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kimco Realty Corporation (HC) Common Stock

No Aura AI signal available yet.

Moderna, Inc.

Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.

Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

KIM

No sentiment data available yet.

MRNA
53% Buy47% Sell
Avg holding period · 59 Days

Top news

Latest headlines on both assets

About Kimco Realty Corporation (HC) Common Stock

Kimco Realty is a real estate investment trust that owns and operates open-air, grocery-anchored shopping centers and mixed-use properties in the United States.

Read more on KIM →

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA →